Lyell Immunopharma Inc reports results for the quarter ended March 31 - Earnings Summary

• Lyell Immunopharma Inc LYEL.OQ reported a quarterly adjusted loss of 18 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -24 cents. The mean expectation of three analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -20 cents to -17 cents per share.

• Revenue rose 133.3% to $7.00 thousand from a year ago; analysts expected zero.

• Lyell Immunopharma Inc's reported EPS for the quarter was a loss of 18 cents​.

• The company reported a quarterly loss of $52.2 million.

• Lyell Immunopharma Inc shares had fallen by 21.6% this quarter and lost 34.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 5.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for Lyell Immunopharma Inc is $0.80

This summary was machine generated from LSEG data May 13 at 10:29 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)